Skip to main content

Tobacco Use Disorder

11
Pipeline Programs
16
Companies
20
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
4
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Cessation Therapeutics
1 program
1
Self-determination Intervention for Tobacco DependencePhase 41 trial
Active Trials
NCT00178685Completed837Est. Aug 2008
Pfizer
PfizerNEW YORK, NY
4 programs
1
VareniclinePhase 21 trial
Deep Repetitive Transcranial Magnetic StimulationN/A
Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in HumansN/A1 trial
VareniclineN/A1 trial
Active Trials
NCT01302262Completed10Est. Mar 2013
NCT01308736Completed73Est. Feb 2014
NCT00595868Completed220Est. Jan 2010
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
Pediatric residency training on tobaccoPhase 21 trial
Modified Project Toward No Tobacco UseN/A1 trial
Active Trials
NCT00059514Completed2,300Est. May 2006
NCT00098215Unknown4,000Est. Feb 2006
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
2 programs
2
Active rTMSPhase 21 trial
Web + PhonePhase 21 trial
Active Trials
NCT03497299Withdrawn0Est. Aug 2022
NCT00820495Completed1,683Est. May 2012
ViiV Healthcare
ViiV HealthcareNC - Durham
3 programs
3
Nicotine Prototype Mini lozengePhase 11 trial
Nicotine Prototype Mini lozengePhase 11 trial
Treatment A: Nicorette 2 mg coated mint gumPhase 11 trial
Active Trials
NCT03541044Completed46Est. Mar 2019
NCT03543137Completed37Est. Nov 2018
NCT02688374Completed45Est. Jun 2016
Grand Medical
Grand MedicalIsrael - Ramat Gan
1 program
1
CHERLPhase 1
GeneSys
GeneSysIndia - Hyderabad
1 program
1
CHERLPhase 11 trial
Active Trials
NCT00269009UnknownEst. Feb 2007
Martin Pharmaceuticals
1 program
1
ModafinilNicotine Replacement TherapyPhase 11 trial
Active Trials
NCT00258479Completed24Est. Dec 2011
GSK
GSKLONDON, United Kingdom
3 programs
Nicotine Prototype Mini lozengePHASE_1
Nicotine Prototype Mini lozengePHASE_1
Treatment A: Nicorette 2 mg coated mint gumPHASE_1
Innovation Pharmaceuticals
2 programs
Control groupN/A1 trial
Quitoxil®N/A1 trial
Active Trials
NCT05885659Unknown90Est. Dec 2025
NCT07722832Not Yet Recruiting606Est. Apr 2028
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
CHERLPHASE_1
Bupropion SRPHASE_41 trial
Active Trials
NCT00119210Terminated40Est. Mar 2006
BrainsWay
BrainsWayJerusalem, Israel
1 program
Deep Repetitive Transcranial Magnetic StimulationN/A1 trial
Active Trials
NCT04083144Completed50Est. Dec 2022
Alliance Pharmaceuticals
1 program
Fresh limeN/A1 trial
Active Trials
NCT01333202Completed100Est. Sep 2009
Hope Medicine
Hope MedicineChina - Pudong
1 program
QuitbuddyN/A1 trial
Active Trials
NCT05625685Withdrawn0Est. Nov 2023
Bryan Corporation
Bryan CorporationOH - Cincinnati
1 program
QuitbuddyN/A
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
repetitive transcranial magnetic stimulationN/A1 trial
Active Trials
NCT03827265Completed60Est. Aug 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Johnson & JohnsonBupropion SR
Cessation TherapeuticsSelf-determination Intervention for Tobacco Dependence
Oregon TherapeuticsActive rTMS
Oregon TherapeuticsWeb + Phone
PfizerVarenicline
Human BioSciencesPediatric residency training on tobacco
ViiV HealthcareNicotine Prototype Mini lozenge
ViiV HealthcareNicotine Prototype Mini lozenge
ViiV HealthcareTreatment A: Nicorette 2 mg coated mint gum
GeneSysCHERL
Martin PharmaceuticalsModafinilNicotine Replacement Therapy
Innovation PharmaceuticalsQuitoxil®
Hope MedicineQuitbuddy
Innovation PharmaceuticalsControl group
BrainsWayDeep Repetitive Transcranial Magnetic Stimulation

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 10,221 patients across 20 trials

NCT00119210Johnson & JohnsonBupropion SR

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

Start: Mar 2005Est. completion: Mar 200640 patients
Phase 4Terminated
NCT00178685Cessation TherapeuticsSelf-determination Intervention for Tobacco Dependence

Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence

Start: Aug 2004Est. completion: Aug 2008837 patients
Phase 4Completed
NCT03497299Oregon TherapeuticsActive rTMS

Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia

Start: Jul 2018Est. completion: Aug 20220
Phase 2Withdrawn
NCT00820495Oregon TherapeuticsWeb + Phone

Effectiveness of a Web-Assisted Quitline for Smokeless Tobacco Users

Start: May 2009Est. completion: May 20121,683 patients
Phase 2Completed
NCT00595868PfizerVarenicline

Efficacy of Varenicline in Ambivalent Smokers

Start: Mar 2008Est. completion: Jan 2010220 patients
Phase 2Completed
NCT00098215Human BioSciencesPediatric residency training on tobacco

Pediatric Residency Training On Tobacco

Start: Mar 2001Est. completion: Feb 20064,000 patients
Phase 2Unknown
NCT03541044ViiV HealthcareNicotine Prototype Mini lozenge

A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers

Start: Jun 2018Est. completion: Mar 201946 patients
Phase 1Completed
NCT03543137ViiV HealthcareNicotine Prototype Mini lozenge

To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

Start: Jun 2018Est. completion: Nov 201837 patients
Phase 1Completed
NCT02688374ViiV HealthcareTreatment A: Nicorette 2 mg coated mint gum

A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers

Start: Mar 2016Est. completion: Jun 201645 patients
Phase 1Completed
NCT00269009GeneSysCHERL

CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change

Start: Jan 2006Est. completion: Feb 2007
Phase 1Unknown
NCT00258479Martin PharmaceuticalsModafinilNicotine Replacement Therapy

Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents

Start: Jun 2003Est. completion: Dec 201124 patients
Phase 1Completed
NCT07722832Innovation PharmaceuticalsQuitoxil®

Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation

Start: Oct 2026Est. completion: Apr 2028606 patients
N/ANot Yet Recruiting
NCT05625685Hope MedicineQuitbuddy

Equitable Smoking Relapse Prevention

Start: Oct 2023Est. completion: Nov 20230
N/AWithdrawn
NCT05885659Innovation PharmaceuticalsControl group

Smoking Cessation Program for Adults With Type 2 Diabetes Mellitus (DiMe-SALUD2 Project)

Start: Sep 2023Est. completion: Dec 202590 patients
N/AUnknown
NCT04083144BrainsWayDeep Repetitive Transcranial Magnetic Stimulation

Deep rTMS and Varenicline for Smoking Cessation

Start: Aug 2019Est. completion: Dec 202250 patients
N/ACompleted
NCT03827265Angeles Therapeuticsrepetitive transcranial magnetic stimulation

Transcranial Magnetic Stimulation and Tobacco Use Disorder

Start: Feb 2019Est. completion: Aug 202460 patients
N/ACompleted
NCT01302262PfizerSmoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Start: Feb 2011Est. completion: Mar 201310 patients
N/ACompleted
NCT01308736PfizerVarenicline

Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit

Start: Jan 2011Est. completion: Feb 201473 patients
N/ACompleted
NCT01333202Alliance PharmaceuticalsFresh lime

Fresh Lime Alone for Smoking Cessation

Start: Mar 2009Est. completion: Sep 2009100 patients
N/ACompleted
NCT00059514Human BioSciencesModified Project Toward No Tobacco Use

Tobacco Use Among Arab American Youth

Start: May 2000Est. completion: May 20062,300 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.